ACCP/ISSX Organ-on-a-chip Webinar Series, Part 2

This is a two-part joint webinar series, co-hosted by ISSX and ACCP. 

Part 2: Technology & Translational Applications, Wednesday, November 11, 2026 1:00 PM – 2:30 PM  (EST)
Speakers: Edward LeCluyse, LifeNet Health and Janny Pineriro-Llanes, University of Florida

Part 2: Safety, Toxicology & Clinical Decision Support, Wednesday, November 18, 2026, 1:00 PM – 2:30 PM  (EST)
Speakers: Edward Kelly, University of Washington and Wendy Wu, FDA

Learners completing this activity will be able to describe the fundamental principles and emerging applications of Organ-on-a-Chip (OoC) technology in clinical pharmacology and drug development. This activity will explore how microengineered systems replicate aspects of human organ structure and function to provide human-relevant models for investigating drug disposition and response. Faculty will discuss applications of OoC systems in preclinical and early-phase drug development, including the evaluation of absorption, distribution, metabolism and excretion (ADME), prediction of metabolic pathways and drug clearance and assessment of enzyme- and transporter-mediated drug–drug interactions. The activity will also examine how OoC-generated data can support pharmacokinetic/pharmacodynamic (PK/PD) analyses, physiologically based pharmacokinetic (PBPK) modeling and translational decision-making, including the prediction of human drug exposure and first-in-human dose selection. Current limitations and challenges related to validation, reproducibility and standardization will also be addressed. 

After completing this activity, the learner will be able to:

• Describe the fundamental principles of Organ-on-a-Chip (OoC) technology and its applications in preclinical and early-phase drug development.
• Identify how OoC systems can be used to investigate drug absorption, distribution, metabolism and excretion (ADME), including drug clearance and drug–drug interactions.
• Explain how OoC-generated data can support pharmacokinetic modeling, prediction of human drug exposure and translational decision-making in drug development.